Comparison of heparin administration using the rapidpoint™ coag and hepcon® HMS

Journal of Extra-Corporeal Technology

Volumn 36, Issue 2, 2004, Pages 139-144

  Newsome, Jason ^a   Stipanovich, Kerri ^a   Flaherty, Sarah ^b  

^a CHARLESTON AREA MEDICAL CENTER   (United States)

^b CAMC Health System   (United States)

Author keywords

Activated clotting time; Cardiopulmonary bypass; Heparin protamine titration; Homologous blood products; Mediastinal drainage

Indexed keywords

HEPARIN; PROTAMINE;

ADULT; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; COMPARATIVE STUDY; DEVICE; DRUG DELIVERY SYSTEM; FEMALE; HEMATOCRIT; HEMODILUTION; HEPARIN MANAGEMENT TEST; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; RETROSPECTIVE STUDY; REVIEW;

EID: 3142701336     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Hattersley PG. Activated coagulation time of whole blood. JAMA. 1966;195:150-4.
2. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation: I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg. 1975;69:674-82.
3. Young J, Kisker T, Doty D. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg. 1978;26:231-40.
4. Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation: II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg. 1975;69:685-9.
5. Kmiecik SA, Liu J, Vaadia TS, et al. Quantitative evaluation of hypothermia, hyperthermia, and hemodilution on coagulation. J Extra Corpor Technol. 2001;33:100-5.
6. Cohen EJ, Camerlengo LJ, Dearing JP. Activated clotting times and cardiopulmonary bypass I: The effect of hemodilution and hypothermia upon activated clotting time. J Extra Corpor Technol. 1980;12:139-41.
7. Bull MH, Huse WM, Bull BS. Evaluation of tests used to monitor heparin therapy during extracorporeal circulation. Anesthesiology. 1975;43:346-53.
8. Despotis GJ, Joist JH, Hogue CW, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. J Thorac Cardiovasc Surg. 1995;110:46-54.
9. Fox DJ, Gaines J, Reed G. Vehicles of heparin management. J Extra Corpor Technol. 1979;11:137-42.
10. Hardy J, Belisle S, Robitaille D, Perrault J, Roy M, Gagnon L. Measurement of heparin concentration in whole blood with the Hepcon/hms device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg. 1996;112:154-61.
11. Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg. 1995;110:36-45.
12. Gravlee GP, Haddon WS, Rothberger HK, et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg. 1990;99:518-27.
13. Olshove V, Tallman R. Heparin use in pediatric bypass - Empirical regimen (ACT) vs. heparin concentration: A multicenter trial. J Extra Corpor Technol. 2000;32:84-8.
14. Turner-Gomes SO, Nitschmann EP, Norman GR, Andrew ME, Williams WG. Effect of heparin loading during congenital heart operation on thrombin generation and blood loss. Ann Thorac Surg. 1997;63:482-8.
15. Gravlee GP, Roger AT, Dudas LM, et al. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology. 1992;76:393-401.
16. Shanberge JN, Murato M, Quattrociocchi-Longe T, Neste LV. Heparin-protamine complexes in the production of heparin rebound and other complications of extracorporeal bypass procedures. Am J Clin Pathol. 1987;87:210-7.
17. Perkins HA, Osborn JJ, Gerbode E. The management of abnormal bleeding following extracorporeal circulation. Ann Intern Med. 1959;51:658-67.
18. Perkins HA, Acra DJ, Rolfs MR. Estimation of heparin levels in stored and traumatized blood. Blood. 1961;18:807-8.
19. Frick PG, Brogli H. The mechanism of heparin rebound after extracorporeal circulation for open cardiac surgery. Surgery. 1966;59:721-9.
20. Ellison N, Beaty P, Blake DR, et al. Heparin rebound. J Thorac Cardiovasc Surg. 1974;67:723-9.
21. Jobes DR, Shaffer GW, Aitken GL. Heparin/protamine dosing guided by in vitro testing reduces blood loss and transfusion in cardiac surgery. Anesthesiology. 1992;77:A137.
22. Medtronic Inc. Heparin assay package insert. 2000.
23. Roche T, Royston D. The rapidpoint heparin management time is not prolonged by aprotinin following heparin doses used prior to cardiopulmonary bypass but is by hemodilution with colloid. Anesth Analg. 2003;96:S-54.
24. Brace LD. Comparison of the ACT and HMT tests for monitoring heparin therapy in the cardiopulmonary bypass suite. Thromb Haemost. 1995;43:1241.
25. Slaughter TF, Grocott H, Greenblo K, et al. The heparin management test (HMT): An improved method for monitoring anticoagulation during cardiac surgery. Arth Rheum. 1996;85:3A.
26. Owings JT, Pollack ME, Gosselin RC, Ireland K. Heparin management test: An improved method of assessing anticoagulation during CPB in the pediatric population. Thromb Haemost. 1995;73:976a.
27. Mertzlefft FO, Koster A, Kuppe H. The heparin management test: In vitro findings for cardiopulmonary bypass. Ann Thorac Surg. 1999;67:1012-7.
28. Fitch J, Geary K, Mirto G, Byrne D, Hines R. Heparin management test vs. activated coagulation time during cardiovascular surgery: Correlation with anti-Xa activity. J Cardiothorac Vasc Anesth. 1999;73:976a.
29. Wallock M, Jeske WP, Bakhos M, Welenga J. Evaluation of a new point of care heparin test for cardiopulmonary bypass: The TAS heparin management test. Perfusion. 2001;16:147-53.
30. Jobes DR, Ellison N, Campbell FW. Limitations for ACT. Anesth Analg. 1989;69:142-4.
31. Marcum JA, Rosenburg RD. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry. 1984;23:1730-7.
32. Marcum JA, Fritze L, Galli SJ, et al. Microvascular heparin-like species with anticoagulant activity. Am J Phys. 1983;245:H725-33.
33. Marcum JA, Rosenburg RD. Heparin-like molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun. 1985;126:365-72.
34. Paul J, Counillon B, Baguet J, Dureau G, Belleville J. In vivo release of heparin-like factor in dogs during profound hypothermia. J Thorac Cardiovasc Surg. 1981;82:45-8.